



8735 West Higgins Rd. Suite 300
Chicago, IL 60631
847-375-4731 Phone
847-375-6429 Fax
info@painmed.org
.....
www.painmed.org

Methadone for Pain Management: Improving Clinical Decision Making

Recommended Prescriber Practices from the American Academy of Pain Medicine

1. Patients with intermittent chronic pain requiring opioid medication only "as needed" or who have a history of medication non-compliance are not good candidates for methadone therapy.
2. Initiate therapy at a low dose – 15 mg or less per day in divided doses; lower doses are recommended for older patients, frail patients, or individuals with at-risk co-morbidities (e.g. COPD).
3. Increase dose no more often than once per week.
4. Increase dose slowly, with total daily dose increases not to exceed 5-10 mg per week.
5. Assess patient's risk for developing a prolonged QT interval and provide appropriate surveillance of ECG. For example, patients with cardiac disease taking other QT interval prolonging drugs, patients with electrolyte abnormalities (renal insufficiency/diuretic therapy/hemodialysis), patients with poorly controlled DM, or patients taking 60-100 mg or more of methadone a day. Repeat ECG following dose increases in these high risk patients. Decrease dose or discontinue therapy if QT interval exceeds 470 milliseconds in men or 480 milliseconds in women (Johnson and Ackerman 2009).
6. Perform StopBANG screening for potential OSA. Evaluate for sleep apnea in patients with a history of sleep-induced airway obstruction or untreated sleep apnea, or patients exceeding 50 mg methadone per day. Prescribing of methadone should be contingent upon compliance with OSA treatments.
7. Don't prescribe for patients with known sleep disordered breathing who are non-compliant with their respiratory assistive devices.
8. Evaluate additional respiratory depressant risk factors related to use of sedatives with methadone.
9. Communicate with patient the critical importance of not using more methadone than directed even if the pain is not well controlled.

10. Use immediate release opioid formulations during methadone dose titrations if the initial dose of methadone is inadequate to manage the pain. Use a dosage of the IR opioid that would be safe but effective. For example, oxycodone 5 mg q 4 hours NTE 6 per day and one week supply.

Outcomes

Standardize the implementation of risk reduction strategies and patient safety practices in prescribing methadone for the treatment of chronic pain.

- Reduce incidence of unintentional opioid associated overdose deaths.
- Reduce incidence of methadone overdoses due to too rapid dose escalation.
- Reduce incidence of methadone overdoses due to too high of a starting dose.
- Reduce incidence of overdoses due to opioid rotation to methadone.
- Reduce the risk of lethal cardiac dysrhythmias due to methadone.

References and Suggested Readings

1. American Society for Pain Management Nursing (2010). Coexisting Addiction and Pain. In B.J. St. Marie (Ed.) *Core Curriculum for Pain Management Nursing, 2nd ed.* Lenexa, KS: ASPMN
2. American Society for Pain Management Nursing Position Statement: Pain Management in Patients with Substance Use Disorders. Volume 13, Issue 3, September 2012, Pages 169–183.
3. Arnstein, P.A., St. Marie, B.J. (2010). Managing Chronic Pain with Opioids: A Call for Change. Retrieved on 6/17/2012, from http://www.nphealthcarefoundation.org/programs/downloads/white_paper_opioids.pdf.
4. Fine PG, Portenoy RK. Ad hoc expert panel on evidence review and guidelines for opioid rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. *Journal of Pain and Symptom Management*. 2009;38(3):418-425.
5. Ghafoor, V.L., St. Marie, B.J. (2010). Overview of Pharmacology. In B.J. St. Marie (Ed.), *Core Curriculum for Pain Management Nursing, 2nd Ed.* Lenexa, KS: ASPMN
6. Grinstead, S. F., Gruber-Grinstead, E. (2011) *Freedom from Suffering: A Journey of Hope*. Independence, MO: Herald House/Independent Press.
7. Johnson JN, Ackerman MJ. QTc: how long is too long? *British Journal of Sports Medicine*. 2009;43(9):657-662. doi:10.1136/bjism.2008.054734.
8. Kao DP, Haigney MC, Mehler PS, Krantz MJ. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. *Addiction*. 2015 Sep;110(9):1468-75. doi: 10.1111/add.13013. PubMed PMID: 26075588; PubMed Central PMCID: PMC4521976.
9. Lintzeris, N, Nielsen, S. Benzodiazepines, Methadone and Buprenorphine: Interactions and Clinical Management. *The American Journal on Addictions*. 2009, 19: 59-72.
10. Ray WA, Chung CP et al. Out-of-Hospital Mortality Among Patients Receiving Methadone for Noncancer Pain. *JAMA Intern Med*. doi:10.1001/jamainternmed.2014.6294.
11. United States FDA. Public Health Advisory: Methadone Use for Pain Control May Result in Death and Life-Threatening Changes in Breathing and Heart Beat. Rockville United States Food and Drug Administration; 2006.

12. Webster LR, et al. An Analysis of the Root Causes for Opioid-Related Overdose Deaths in the United States. *Pain Medicine* 2011, 12; S26-S35.
13. Webster LR. Methadone-related deaths. *J Opioid Manage* 2005 Sep-Oct;1(4):211-7.
14. Webster LR, Fine PG. Review Article: Review and Critique of Opioid Rotation Practices and Associated Risks of Toxicity. *Pain Medicine* 2012;13:562-570.